<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Crit Care</journal-id><journal-id journal-id-type="iso-abbrev">Crit Care</journal-id><journal-title-group><journal-title>Critical Care</journal-title></journal-title-group><issn pub-type="ppub">1364-8535</issn><issn pub-type="epub">1466-609X</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">4068371</article-id><article-id pub-id-type="publisher-id">cc13432</article-id><article-id pub-id-type="doi">10.1186/cc13432</article-id><article-categories><subj-group subj-group-type="heading"><subject>Poster Presentation</subject></subj-group></article-categories><title-group><article-title>Effect of clarithromycin in patients with Gram-negative sepsis: subgroup analysis of a randomized trial</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Giamarellos-Bourboulis</surname><given-names>E</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A2"><name><surname>Lymberopoulou</surname><given-names>K</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A3"><name><surname>Tsangaris</surname><given-names>I</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib><contrib contrib-type="author" id="A4"><name><surname>Antonopoulou</surname><given-names>A</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib><contrib contrib-type="author" id="A5"><name><surname>Marioli</surname><given-names>A</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A6"><name><surname>Leonidou</surname><given-names>L</given-names></name><xref ref-type="aff" rid="I4">4</xref></contrib><contrib contrib-type="author" id="A7"><name><surname>Douzinas</surname><given-names>E</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib><contrib contrib-type="author" id="A8"><name><surname>Koutelidakis</surname><given-names>I</given-names></name><xref ref-type="aff" rid="I5">5</xref></contrib><contrib contrib-type="author" id="A9"><name><surname>Armaganidis</surname><given-names>A</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib></contrib-group><aff id="I1"><label>1</label>University of Athens, Medical School, Athens, Greece</aff><aff id="I2"><label>2</label>Sismanogleion General Hospital, Athens, Greece</aff><aff id="I3"><label>3</label>University of Athens, Athens, Greece</aff><aff id="I4"><label>4</label>University of Patras, Rion, Greece</aff><aff id="I5"><label>5</label>Aristotle University, Thessaloniki, Greece</aff><pub-date pub-type="ppub"><year>2014</year></pub-date><pub-date pub-type="epub"><day>17</day><month>3</month><year>2014</year></pub-date><volume>18</volume><issue>Suppl 1</issue><supplement><named-content content-type="supplement-title">34th International Symposium on Intensive Care and Emergency Medicine</named-content><named-content content-type="supplement-sponsor">Publication of this supplement was supported by ISICEM.</named-content></supplement><fpage>P242</fpage><lpage>P242</lpage><permissions><copyright-statement>Copyright &#x000a9; 2014 Giamarellos-Bourboulis et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>Giamarellos-Bourboulis et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><self-uri xlink:href="http://ccforum.com/content/18/S1/P242"/><conference><conf-date>18-21 March 2014</conf-date><conf-name>34th International Symposium on Intensive Care and Emergency Medicine</conf-name><conf-loc>Brussels, Belgium</conf-loc></conference></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>A recent randomized trial of our group showed that blind treatment with clarithromycin decreased mortality from septic shock and multiple organ dysfunction, shortened time until resolution of infection in patients with severe sepsis/shock and decreased hospitalization costs [<xref ref-type="bibr" rid="B1">1</xref>]. The efficacy of clarithromycin in relation with the type of failing organs is analyzed.</p></sec><sec sec-type="methods"><title>Methods</title><p>Six hundred patients with systemic inflammatory response syndrome due to primary Gram-negative bacteremia or acute pyelonephritis or intraabdominal infection were blindly assigned to placebo or clarithromycin for four consecutive days as adjunctive treatment to standard of care. Clarithromycin was administered at a dose of 1 g once daily in 1 hour of continuous infusion. Organ failures before allocation to blind treatment were defined according to the Surviving Sepsis Campaign 2003 definitions. Cox regression analysis was done to verify the effect of clarithromycin as a moderator. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated.</p></sec><sec sec-type="results"><title>Results</title><p>Forty-nine patients of the placebo arm and 55 patients of the clarithromycin arm had acute lung injury (ALI); mortality was 51.0% and 30.9% respectively (<italic>P </italic>= 0.046). Forty-seven patients of the placebo arm and 54 patients of the clarithromycin arm had acute coagulopathy; mortality was 44.7% and 44.4% respectively (<italic>P </italic>= 1.000). Twenty patients of the placebo arm and 19 patients of the clarithromycin arm had metabolic acidosis; mortality was 55.0% and 52.6% respectively (<italic>P </italic>= 1.000). Twenty-nine patients of the placebo arm and 39 patients of the clarithromycin arm had acute oliguria; mortality was 55.2% and 48.7% respectively (<italic>P </italic>= 0.631). ALI (HR = 2.42; 95% CI = 1.45 to 4.03, <italic>P </italic>= 0.001), acute coagulopathy (HR = 2.65; CI = 1.69 to 4.16) and cardiovascular failure (HR = 3.36, CI = 2.09 to 5.39) were independently associated with unfavorable outcome. Adding treatment with clarithromycin in the equation reduced the risk for death by ALI by 1.86-fold (HR = 0.54; CI = 0.29 to 0.99, <italic>P </italic>= 0.049).</p></sec><sec sec-type="conclusions"><title>Conclusion</title><p>Clarithromycin is a major moderator of the physical course of Gram-negative sepsis complicated with ALI.</p></sec></body><back><ref-list><ref id="B1"><mixed-citation publication-type="other"><name><surname>Giamarellos-Bourboulis</surname><given-names>EK</given-names></name><etal/><source>J Antimicrob Chemother</source><year>2013</year></mixed-citation></ref></ref-list></back></article>